Tags

Type your tag names separated by a space and hit enter

Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer.
J Formos Med Assoc. 2003 Dec; 102(12):857-62.JF

Abstract

BACKGROUND AND PURPOSE

Rabeprazole is a new proton pump inhibitor producing rapid inhibition of gastric acid secretion. This may potentiate the inhibitory effect of antibiotics against Helicobacter pylori. This study compared the efficacy, safety, and tolerability of 4- and 7-day rabeprazole-based triple therapies versus 7-day omeprazole-based triple therapy.

METHODS

A total of 70 H. pylori-infected peptic ulcer patients were randomly assigned to 1 of 3 groups: RAC4 (rabeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 4 days), RAC7 (rabeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days), and OAC7 (omeprazole 20mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days). Endoscopy, Campylobacter-like organism (CLO) test, H. pylori culture, and 13C-urea breath test were performed before randomization and 8 weeks after the start of triple therapy.

RESULTS

Intention-to-treat (ITT) eradication rates for the RAC4, RAC7, and OAC7 groups were 87% (20/23), 83%(19/23), and 88% (21/24), respectively, and per-protocol (PP) eradication rates were 91% (20/22), 95% (19/20), and 100% (21/21), respectively. There was no significant difference among the ITT or PP eradication rates of the 3 groups. All 3 regimens were well tolerated and compliance was excellent.

CONCLUSIONS

One-week RAC and 1-week OAC are equally effective for H. pylori eradication in peptic ulcer patients. The duration of RAC triple therapy can be shortened to 4 days without compromising its efficacy.

Authors+Show Affiliations

Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

14976565

Citation

Yang, Kuo-Ching, et al. "Comparison of Rabeprazole-based Four- and Seven-day Triple Therapy and Omeprazole-based Seven-day Triple Therapy for Helicobacter Pylori Infection in Patients With Peptic Ulcer." Journal of the Formosan Medical Association = Taiwan Yi Zhi, vol. 102, no. 12, 2003, pp. 857-62.
Yang KC, Wang GM, Chen JH, et al. Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer. J Formos Med Assoc. 2003;102(12):857-62.
Yang, K. C., Wang, G. M., Chen, J. H., Chen, T. J., & Lee, S. C. (2003). Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer. Journal of the Formosan Medical Association = Taiwan Yi Zhi, 102(12), 857-62.
Yang KC, et al. Comparison of Rabeprazole-based Four- and Seven-day Triple Therapy and Omeprazole-based Seven-day Triple Therapy for Helicobacter Pylori Infection in Patients With Peptic Ulcer. J Formos Med Assoc. 2003;102(12):857-62. PubMed PMID: 14976565.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer. AU - Yang,Kuo-Ching, AU - Wang,Gen-Ming, AU - Chen,Jui-Hao, AU - Chen,Tong-Jong, AU - Lee,Shui-Cheng, PY - 2004/2/21/pubmed PY - 2004/5/27/medline PY - 2004/2/21/entrez SP - 857 EP - 62 JF - Journal of the Formosan Medical Association = Taiwan yi zhi JO - J Formos Med Assoc VL - 102 IS - 12 N2 - BACKGROUND AND PURPOSE: Rabeprazole is a new proton pump inhibitor producing rapid inhibition of gastric acid secretion. This may potentiate the inhibitory effect of antibiotics against Helicobacter pylori. This study compared the efficacy, safety, and tolerability of 4- and 7-day rabeprazole-based triple therapies versus 7-day omeprazole-based triple therapy. METHODS: A total of 70 H. pylori-infected peptic ulcer patients were randomly assigned to 1 of 3 groups: RAC4 (rabeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 4 days), RAC7 (rabeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days), and OAC7 (omeprazole 20mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days). Endoscopy, Campylobacter-like organism (CLO) test, H. pylori culture, and 13C-urea breath test were performed before randomization and 8 weeks after the start of triple therapy. RESULTS: Intention-to-treat (ITT) eradication rates for the RAC4, RAC7, and OAC7 groups were 87% (20/23), 83%(19/23), and 88% (21/24), respectively, and per-protocol (PP) eradication rates were 91% (20/22), 95% (19/20), and 100% (21/21), respectively. There was no significant difference among the ITT or PP eradication rates of the 3 groups. All 3 regimens were well tolerated and compliance was excellent. CONCLUSIONS: One-week RAC and 1-week OAC are equally effective for H. pylori eradication in peptic ulcer patients. The duration of RAC triple therapy can be shortened to 4 days without compromising its efficacy. SN - 0929-6646 UR - https://www.unboundmedicine.com/medline/citation/14976565/Comparison_of_rabeprazole_based_four__and_seven_day_triple_therapy_and_omeprazole_based_seven_day_triple_therapy_for_Helicobacter_pylori_infection_in_patients_with_peptic_ulcer_ L2 - https://medlineplus.gov/pepticulcer.html DB - PRIME DP - Unbound Medicine ER -